MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Summary

Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.

Timeline

Start

2026-02

Primary completion

2029-01

Completion

2029-01

Drugs

Indications